Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
*Purpose: This study evaluates if choice and duration of Cytomegalovirus (CMV) prophylaxis based on donor (D) and recipient (R) CMV serostatus impacts the incidence of post-transplant CMV viremia in low (D-/R-) and intermediate (R+) risk kidney transplant recipients (KTR) receiving lymphocyte-depleting induction therapy.
*Methods: Adult D-/R- and R+ KTR receiving anti-thymocyte globulin [rabbit] (rATG) or alemtuzumab induction at our institution from 8/20/16-9/30/18 were evaluated through 1 year post-transplant. Patients were excluded if they were CMV D+/R-, received a multi-organ transplant, or received basiliximab. Historically, this population received 6 months of valganciclovir (pre-intervention group). After an institutional practice change, D-/R- patients received valacyclovir for 3 months and R+ patients received valganciclovir for 3 months (post-intervention group). Fisher’s exact test was used to compare categorical data and the Student’s t or Mann-Whitney U test was used for continuous data. Statistical significance was set at α=0.05.
*Results: Baseline characteristics are described in Table 1 (D-/R- n=25, R+ n=52). No D-/R- patients experienced CMV viremia. Among the R+ pre- and post- groups, there was no significant difference in viremia incidence (41.9% vs. 52.4%, p=0.573; Table 2) nor the initial viral load (median, IQR; <50, <50-91 vs. <50, <50-217; p=0.865; Table 2). Neither group showed a significant difference in the incidence of leukopenia or neutropenia (LN); however, a trend toward increased incidence was seen in the D-/R- pre- compared to the post- group (75.0% vs 23.4%, p=0.081; Table 2). No D-/R- patients experienced rejection. Seven R+ patients experienced rejection in the pre- group and one in the post- group (p=0.122).
*Conclusions: A similar incidence in CMV viremia between the pre- and post-intervention groups suggests a more aggressive CMV prophylaxis may not be necessary in low and intermediate risk KTR receiving rATG or alemtuzumab . The trends toward reduced incidence of LN and rejection in the post- groups suggest potential benefits in limiting valganciclovir exposure.
To cite this abstract in AMA style:Stamps H, Linder K, O'Sullivan D, Cheema F, Kutzler H. Evaluation of Cytomegalovirus Prophylaxis in Low and Intermediate Risk Kidney Transplant Recipients Receiving Lymphocyte-Depleting Induction [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/evaluation-of-cytomegalovirus-prophylaxis-in-low-and-intermediate-risk-kidney-transplant-recipients-receiving-lymphocyte-depleting-induction/. Accessed October 28, 2020.
« Back to 2020 American Transplant Congress